Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double blind, placebo controlled Phase 2 study comparing the effects of ARA 290 on neuropathic symptoms of patients with type 2 diabetes.

Trial Profile

A double blind, placebo controlled Phase 2 study comparing the effects of ARA 290 on neuropathic symptoms of patients with type 2 diabetes.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cibinetide (Primary)
  • Indications Diabetic neuropathies; Neuropathic pain; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARAND
  • Most Recent Events

    • 15 Dec 2014 Results published in North Shore-Long Island Jewish Health System media release.
    • 15 Dec 2014 Results have been published in Molecular Medicine, according to a North Shore-Long Island Jewish Health System media release.
    • 15 Dec 2014 Status changed from recruiting to completed, according to a media release reporting results have been published.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top